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Introduction
Dihydrofolate reductase (DHFR)-mediated gene amplifica-
tion has been widely used to establish high-producing
mammalian cell lines [1-3]. However, since gene amplifica-
tion is an infrequent event, in that many rounds of metho-
trexate (MTX) selection to amplify the transgene and
screening of over several hundred individual clones are
required to obtain cells with high gene copy numbers [4].
Consequently, the process for DHFR-mediated gene
amplification is a time-consuming and laborious step for
cell line construction. Here, we present a novel concept to
accelerate gene amplification through cell cycle checkpoint
engineering [5]. In our knowledge, there is no previous
report which focused on controlling cell cycle checkpoint
to enhance the efficiency of DHFR gene amplification
system.
Materials and methods
A small interfering RNA (siRNA) expression vector
against Ataxia-Telangiectasia and Rad3-Related (ATR), a
cell cycle checkpoint kinase, was transfected into Chinese
hamster ovary (CHO) cells. The effects of ATR down-
regulation on gene amplification and productivity in
CHO cells producing green fluorescent protein (GFP)
and monoclonal antibody (mAb) were investigated.
Results and discussion
Analysis of GFP expression level during gene
amplification process
The ratio of GFP-expressing cells was evaluated by flow
cytometry analysis during the gene amplification process
at 100-, 250-, and 500-nM MTX concentrations. In the
process of gene amplification at all MTX concentrations,
the pools of ATR-downregulated cells showed a much
higher percentage of GFP-positive cells as compared
with the pools of mock cells. At 100-nM MTX concen-
tration, the percentage of GFP-positive cells in the
CHO-siATR cell pool was 18.7 % of total cells, which
was approximately twice of the 8.4 % in the mock cells.
At 250- and 500-nM MTX concentrations, CHO-siATR
cell pools had 28.6 and 39.2 % GFP-positive cells,
respectively, which were up to six times higher than the
4.6 and 6.8 % of the pools of mock cells.
Comparison of IgG productivity
IgG-producing cell lines were generated to confirm the pre-
vious results obtained in GFP-producing cell lines. The
ATR-downregulated cells showed a significant increase in
specific production rate of an average of 0.08 pg cell−1 day−1,
which was approximately four times higher than the average
of 0.02 pg cell−1 day−1 in the mock cells. The volumetric
productivity of each cell line was also investigated to evalu-
ate the influence of ATR downregulation. The volumetric
productivity of ATR knockdown cells was an average of
0.035 mg L−1 day−1, which was approximately three times
higher than the average of 0.013 mg L−1 day−1 of the mock
cells, suggesting that ATR knockdown generated the pool of
higher-producing cells during the gene amplification
process.
Estimation of amplified transgene copy number
Quantitative real-time PCR was used to estimate the
amplified transgene copy number of GFP-producing cell
lines during the gene amplification process. The average
copy number of ATR-downregulated cells was 15.4 ±
0.8, 27.6 ± 0.3, and 62.0 ± 2.9 at 100-, 250-, and
500-nM MTX concentrations, respectively. These num-
bers were up to 24 times higher than 3.98 ± 0.09, 2.20 ±
0.03, and 2.59 ± 0.07 of the mock cells. Interestingly,
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the amplified transgene copy numbers in the pools of
ATR-downregulated cells were increased proportionally
with the MTX concentration. The amplified transgene
copy numbers in the IgG-producing cells were also
investigated during the gene amplification process at
100-nM MTX concentration. The amplified light- and
heavy-chain copy numbers of the pool of ATR knock-
down cells were 13.2 ± 3.8 and 11.8 ± 1.8, respectively,
which were up to seven times higher than 6.95 ± 0.07
and 1.68 ± 0.04 of the mock cells. The results from
both the GFP- and IgG-producing cells showed that the
pools of ATR-downregulated cells had much higher
amplified transgene copy numbers as compared with the
pools of mock cells during the gene amplification
process.
Conclusions
In conclusion, we have demonstrated that gene amplifi-
cation can be accelerated by the downregulation of a
cell cycle checkpoint kinase, ATR, and a pool of high-
producing cells can be rapidly derived in a short time
after MTX treatment. This novel method focuses on
generating more high-producing cells in a heteroge-
neous pool as compared with the conventional method
and would thus contribute to reducing the time and
labor required for cell line establishment by increasing
the possibility of selecting high-producing clones.
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